NEW YORK (GenomeWeb News) - 454 Life Sciences said on Friday that it has collaborated with the Yale University School of Medicine to use its sequencing technology to identify previously undetectable drug-resistant HIV variants at an early stage.
 
The study authors said that current genotyping technology can only detect resistance mutations at levels of approximately 20 percent or greater, but sequencing is able to detect resistance mutations at the 1 percent level.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.